跳转至内容
Merck
CN

S6319

盐酸舍曲林 盐酸盐

≥98% (HPLC), Selective serotonin reuptake inhibitor (SSRI), powder

别名:

盐酸舍曲林, (1S,4S)-4-（3,4-二氯苯基）-1,2,3,4-四氢-N-甲基-1-萘胺 盐酸盐

登录 查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C17H17NCl2 · HCl
化学文摘社编号:
79559-97-0
分子量:
342.69
MDL编号:
MFCD00895772
UNSPSC代码:
12352200
PubChem化学物质编号:
24278601
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

盐酸舍曲林 盐酸盐, ≥98% (HPLC)

质量水平

100

方案

≥98% (HPLC)

表单

powder

旋光性

[α]/D +33 to +43°, c = 2.0 in methanol

储存条件

desiccated

颜色

white

溶解性

DMSO: >20 mg/mL

SMILES字符串

ClC1=C(Cl)C=CC([C@H]2C3=C(C=CC=C3)[C@@H](NC)CC2)=C1.[H]Cl

InChI

1S/C17H17Cl2N.ClH/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11;/h2-6,8,10,12,17,20H,7,9H2,1H3;1H/t12-,17-;/m0./s1

InChI key

BLFQGGGGFNSJKA-XHXSRVRCSA-N

基因信息

human ... HTR1A(3350), HTR1B(3351), HTR1D(3352), HTR1E(3354), HTR1F(3355), HTR2A(3356), HTR2B(3357), HTR2C(3358), HTR3A(3359), HTR3B(9177), HTR3C(170572), HTR3D(200909), HTR3E(285242), HTR4(3360), HTR5A(3361), HTR5B(645694), HTR6(3362), HTR7(3363), SLC6A4(6532)

正在寻找类似产品? 访问 产品对比指南

相关类别

应用

在长期准备好的绵羊胎儿中研究了盐酸舍曲林暴露的影响。将其用于糖皮质激素功能测定，研究抗抑郁药对人体糖皮质激素受体功能的影响。

生化/生理作用

舍曲林抑制血小板功能，显示抗血小板和内皮保护功能。缓解抑郁症，提高心血管疾病患者的生活质量。 也可开处方治疗帕金森病的抑郁症状。
选择性 5-羟色胺再摄取抑制剂，抗抑郁药。

特点和优势

该化合物收录于 受体分类和信号转导手册的《生物胺转运体 》页面。想要浏览手册的其他页面， 请单击此处。
这种化合物是ADME毒性研究的特色产品。点击此处发现更多特色ADME毒性产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

警示用语：

Warning

危险声明

H302,H373,H410

危险分类

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - STOT RE 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000450078
0000450080
0000450080
0000450078
0000303060

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Celeste M Sheftel et al.
Physiological reports, 10(5), e15204-e15204 (2022-03-03)
Women mobilize up to 10% of their bone mass during lactation to provide milk calcium. About 8%-13% of mothers use selective serotonin reuptake inhibitors (SSRI) to treat peripartum depression, but SSRIs independently decrease bone mass. Previously, peripartal use of the
Hannah P Fricke et al.
Frontiers in pharmacology, 14, 1244580-1244580 (2023-12-11)
Postpartum depression affects many individuals after parturition, and selective serotonin reuptake inhibitors (SSRIs) are often used as the first-line treatment; however, both SSRIs and lactation are independently associated with bone loss due to the role of serotonin in bone remodeling.
Elien Heylen et al.
British journal of cancer, 128(10), 1862-1878 (2023-03-19)
One-third of cancers activate endogenous synthesis of serine/glycine, and can become addicted to this pathway to sustain proliferation and survival. Mechanisms driving this metabolic rewiring remain largely unknown. NKX2-1 overexpressing and NKX2-1 knockdown/knockout T-cell leukaemia and lung cancer cell line
Cassidy Delaney et al.
American journal of physiology. Lung cellular and molecular physiology, 301(6), L937-L944 (2011-09-13)
Maternal use of selective serotonin (5-HT) reuptake inhibitors (SSRIs) is associated with an increased risk for persistent pulmonary hypertension of the newborn (PPHN), but little is known about 5-HT signaling in the developing lung. We hypothesize that 5-HT plays a
Hannah P Fricke et al.
Physiological reports, 11(23), e15881-e15881 (2023-11-30)
At the end of gestation, fetal skeleton rapidly accumulates calcium, and bone development continues in offspring postnatally. To accommodate, maternal skeletal physiology is modulated in a serotonin-dependent manner. Selective serotonin reuptake inhibitors (SSRIs) are generally considered safe for treatment of
查看所有相关文献

商品

Discover Bioactive Small Molecules for ADME/Tox

Discover Bioactive Small Molecules for ADME/Tox

Chromatograms

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持